Pevonedistat hydrochloride is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData, Phase I drugs for Post-Polycythemia Vera Myelofibrosis (PPV-MF) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pevonedistat hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pevonedistat hydrochloride overview
Pevonedistat (MLN4924) is under development for the treatment of myelodysplastic syndrome, recurrent ovarian cancer, hematologic malignancies such as acute myelocytic leukemia, high risk myelodysplastic syndrome, relapsed/refractory multiple myeloma, myelofibrosis and chronic myelomonocytic leukemia, acute lymphocytic leukemia, essential thrombocythemia, post-polycythemia vera myelofibrosis (PPV-MF). It is administered through intravenous route. It is a small molecule which acts by targeting NEDD8 Activating Enzyme (NAE) with potent anti-tumor activity. It was also under development for diffuse large B-cell lymphoma, Waldenstrom's macroglobulinemia, Hodgkin lymphoma, mantle cell lymphoma, metastatic melanoma and solid tumors including ovarian cancer, hepatocellular carcinoma, lung cancer, colon cancer, relapsed and refractory acute lymphocytic leukemia.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. Takeda Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Pevonedistat hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.